Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes…

Purpose To define a gene expression profile of BRCAness that correlates with chemotherapy
response and outcome in epithelial ovarian cancer (EOC). Methods A publicly available …

Importance Patients with recurrent ovarian carcinoma frequently develop resistance to
platinum-based chemotherapy, at which time treatment options become limited. Objective To …

Background High-grade serous ovarian cancers show increased replication stress, rendering
cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (…

The involvement of the RAS superfamily of monomeric GTPases in carcinogenesis is
increasingly being appreciated. A complex array of post-translational modifications and a highly …

Resistance to platinum-based chemotherapy develops in the majority of patients with epithelial
ovarian cancer (EOC). Platinum compounds form electrophilic intermediates that mediate …

PURPOSE To provide recommendations on genetic and tumor testing for women diagnosed
with epithelial ovarian cancer based on available evidence and expert consensus. …

Large-scale genomic studies have shown that half of epithelial ovarian cancers (EOCs)
have alterations in genes regulating homologous recombination (HR) repair 1 . Loss of HR …

Cells deficient in the Brca1 and Brca2 genes have reduced capacity to repair DNA double-strand
breaks by homologous recombination and consequently are hypersensitive to DNA-…

Importance Immune checkpoint inhibitor therapy has shown benefit in various cancers, but
their potential in endometrial cancer (EC) is unknown. Observations Prediction of neoantigen …